Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis. Elafibranor demonstrates significant improvements in biomarkers of disease progression versus pla...
Cash and cash equivalents totaled €93.9 million as of September 30, 2023 Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the...
GENFIT to lead 3 key events on ACLF during AASLD: ACLF Day for Investors/Analysts on November 11, 2023 Patient Advocacy Council meeting on November 11, 2023 ACLF Investigator event on November 12, 2023 Detailed interim data from the ELATIVE ® P...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); September 2 6 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patie...
Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE ® trial in June 2023, paving the way to: a potential submission to the health authorities by Ipsen, and a pote...
2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); August 10 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with...
2023-06-30 06:07:11 ET Stock index futures rose early Friday following strong U.S. economic data , which grew much more than initially thought in the first quarter. The focus is now on the U.S. personal consumption expenditures price index, or the Fed's favorite inflation ...
Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Results position elafi...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with ra...
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...